Michael L. Cheng

4.0k total citations
43 papers, 1.0k citations indexed

About

Michael L. Cheng is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Michael L. Cheng has authored 43 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Cancer Research, 19 papers in Pulmonary and Respiratory Medicine and 18 papers in Oncology. Recurrent topics in Michael L. Cheng's work include Cancer Genomics and Diagnostics (17 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Michael L. Cheng is often cited by papers focused on Cancer Genomics and Diagnostics (17 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Michael L. Cheng collaborates with scholars based in United States, Australia and United Kingdom. Michael L. Cheng's co-authors include Lawrence Fong, Geoffrey R. Oxnard, Mark M. Awad, Biagio Ricciuti, Mizuki Nishino, Atish D. Choudhury, Heather A. Parsons, Glenn J. Hanna, Eirini Pectasides and Lynette M. Sholl and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and Blood.

In The Last Decade

Michael L. Cheng

40 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael L. Cheng United States 17 508 367 346 338 218 43 1.0k
Xiaofan Lu China 17 245 0.5× 406 1.1× 391 1.1× 279 0.8× 119 0.5× 60 938
Christopher G. Przybycin United States 20 187 0.4× 855 2.3× 676 2.0× 300 0.9× 127 0.6× 56 1.5k
Eric Q. Konnick United States 18 329 0.6× 345 0.9× 306 0.9× 367 1.1× 34 0.2× 42 955
Zhenya Tang United States 20 335 0.7× 189 0.5× 375 1.1× 177 0.5× 139 0.6× 111 1.2k
Lisa M. Cordes United States 20 1.2k 2.3× 412 1.1× 308 0.9× 124 0.4× 522 2.4× 105 1.6k
Julia Jückstöck Germany 17 969 1.9× 305 0.8× 356 1.0× 698 2.1× 88 0.4× 38 1.3k
Poonam Vohra United States 13 181 0.4× 162 0.4× 108 0.3× 113 0.3× 31 0.1× 56 545
E. Jaeger Germany 16 621 1.2× 463 1.3× 408 1.2× 105 0.3× 413 1.9× 39 1.2k
Jeanette Dupont Jensen Denmark 17 418 0.8× 219 0.6× 252 0.7× 351 1.0× 13 0.1× 31 838
John E. Mullinax United States 19 681 1.3× 408 1.1× 221 0.6× 153 0.5× 204 0.9× 71 1.2k

Countries citing papers authored by Michael L. Cheng

Since Specialization
Citations

This map shows the geographic impact of Michael L. Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael L. Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael L. Cheng more than expected).

Fields of papers citing papers by Michael L. Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael L. Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael L. Cheng. The network helps show where Michael L. Cheng may publish in the future.

Co-authorship network of co-authors of Michael L. Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Michael L. Cheng. A scholar is included among the top collaborators of Michael L. Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael L. Cheng. Michael L. Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Popescu, Bogdan, Matthew F. Jones, Cheryl A.C. Peretz, et al.. (2025). Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Blood. 147(3). 276–289. 1 indexed citations
2.
Schram, Alison M., Abdul Rafeh Naqash, Eric B. Haura, et al.. (2025). The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial. Clinical Cancer Research. 31(23). 4933–4943.
3.
Baik, Christina S., Michael L. Cheng, Martin Dietrich, Jhanelle E. Gray, & Nagla Abdel Karim. (2024). A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer. Advances in Therapy. 41(7). 2586–2605. 1 indexed citations
4.
Walmsley, Charlotte S., Philip Jonsson, Michael L. Cheng, et al.. (2024). Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy. npj Precision Oncology. 8(1). 34–34. 7 indexed citations
5.
Coté, Gregory M., Bose Kochupurakkal, T. Khanh, et al.. (2024). A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors. Clinical Cancer Research. 31(1). 35–44. 4 indexed citations
6.
Cheng, Michael L., Jaclyn LoPiccolo, Mizuki Nishino, et al.. (2023). Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation. JCO Precision Oncology. 7(7). e2200633–e2200633. 4 indexed citations
7.
Cheng, Michael L., Jessica Lee, Rachit Kumar, et al.. (2022). Response to MEK Inhibitor Therapy inMAP2K1(MEK1) K57N Non–Small-Cell Lung Cancer and Genomic Landscape ofMAP2K1Mutations in Non–Small-Cell Lung Cancer. JCO Precision Oncology. 6(6). e2200382–e2200382. 4 indexed citations
8.
Schneider, Jaime L., Alona Muzikansky, W. Marston Linehan, et al.. (2022). A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib. JTO Clinical and Research Reports. 3(7). 100347–100347. 13 indexed citations
9.
Cheng, Michael L., Marina S.D. Milan, Arrien A. Bertram, et al.. (2021). Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC. JCO Precision Oncology. 5(5). 726–732. 15 indexed citations
10.
Cheng, Michael L., Christie J. Lau, Marina S.D. Milan, et al.. (2021). Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC. JCO Precision Oncology. 5(5). 393–402. 20 indexed citations
11.
Ricciuti, Biagio, Gonzalo Recondo, Liam F. Spurr, et al.. (2020). Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(15). 4135–4142. 102 indexed citations
12.
Cheng, Michael L., Eirini Pectasides, Glenn J. Hanna, et al.. (2020). Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. CA A Cancer Journal for Clinicians. 71(2). 176–190. 124 indexed citations
13.
Sands, Jacob, Tom Nguyen, Priyanka Shivdasani, et al.. (2019). Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. Lung Cancer. 140. 35–41. 30 indexed citations
14.
Cheng, Michael L., Maha Shady, C Cipolla, et al.. (2017). Comparison of somatic mutation profiles from cell free DNA (cfDNA) versus tissue in metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 35(15_suppl). 4533–4533. 3 indexed citations
15.
Cheng, Michael L., Li Zhang, Margaret Borok, et al.. (2015). The incidence of oesophageal cancer in Eastern Africa: Identification of a new geographic hot spot?. Cancer Epidemiology. 39(2). 143–149. 48 indexed citations
16.
17.
Cheng, Michael L. & Lawrence Fong. (2014). Effects of RANKL-Targeted Therapy in Immunity and Cancer. Frontiers in Oncology. 3. 329–329. 66 indexed citations
18.
Cheng, Michael L. & Lawrence Fong. (2014). Beyond Sipuleucel-T: Immune Approaches to Treating Prostate Cancer. Current Treatment Options in Oncology. 15(1). 115–126. 14 indexed citations
19.
Yu, Xu G., Mathias Lichterfeld, Elizabeth T. Kalife, et al.. (2005). High degree of inter-clade cross-reactivity of HIV-1-specific T cell responses at the single peptide level. AIDS. 19(14). 1449–1456. 25 indexed citations
20.
Cheng, Michael L., et al.. (1998). Productivity prediction from well logs in variable grain size reservoirs, Cretaceous Qishn Clastics, Republic of Yemen. ˜The œLog analyst. 40(1). 123–124. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaofan Lu Breakdown of academic impact, for papers by Christopher G. Przybycin Breakdown of academic impact, for papers by Eric Q. Konnick Breakdown of academic impact, for papers by Zhenya Tang Breakdown of academic impact, for papers by Lisa M. Cordes Breakdown of academic impact, for papers by Julia Jückstöck Breakdown of academic impact, for papers by Poonam Vohra Breakdown of academic impact, for papers by E. Jaeger Breakdown of academic impact, for papers by Jeanette Dupont Jensen Breakdown of academic impact, for papers by John E. Mullinax
Rankless by CCL
2026